What is Ubiquigent?
Ubiquigent has carved a niche in the biotechnology sector by focusing on the intricate mechanisms of the ubiquitin-proteasome system and its associated DUB enzymes. The company is recognized for its robust expertise and a distinctive portfolio of specialist services designed to advance research in this complex biological pathway. However, it is important to note that Ubiquigent is currently undergoing a brand transition to a new owner and is no longer directly providing access to its reagents or services. This strategic shift indicates a potential consolidation or evolution within the DUB enzyme research space.
How much funding has Ubiquigent raised?
Ubiquigent has raised a total of $808K across 1 funding round:
Unspecified
$808K
Unspecified (2013): $808K with participation from Scottish Investment Bank and IP Group plc
Key Investors in Ubiquigent
Scottish Investment Bank
Scottish Investment Bank, part of Scottish Enterprise, is a national economic development agency focused on fostering business growth and innovation within Scotland. They provide strategic capital and support to companies across various sectors.
IP Group plc
IP Group plc is a prominent intellectual property commercialization company that invests in and supports university spin-outs and early-stage technology businesses. They offer a blend of capital, strategic guidance, and operational expertise, with a focus on life sciences and technology.
What's next for Ubiquigent?
The recent major strategic investment, alongside the overall enterprise-level funding Ubiquigent has attracted, suggests a company poised for significant advancements, despite its current transition phase. While Ubiquigent itself is no longer directly offering its services, the transfer of its brand to a new owner implies that its legacy and expertise in DUB enzyme research will likely continue under new stewardship. Future support for research in the ubiquitin-proteasome system may be available from the acquiring entity, indicating a potential for continued innovation and development in this specialized area of drug discovery and biological research.
See full Ubiquigent company page
